bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
bluebird bio, Inc. (“bluebird bio” or the “Company”) today announced that it has entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV), if received, in connection with the potential approval of lovotibeglogene autotemcel (lovo-cel) for sickle cell disease. Under the terms of the agreement, rights......